Catalyst Wire Dossier Catalyst Wire Dossier

Tucidinostat

tucidinostat · Chipscreen Biosciences, Ltd.
Drug timelines are a Plus or Pro feature.

16 regulatory and trial events tracked for Tucidinostat, covering 2021-08-11 to 2026-04-20. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC [Phase 2]

See pricing